2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-PP02.57

PP02.57 - Mao Yuxin

Pdf Summary

The study aimed to explore the factors influencing cancer-related fatigue (CRF) and its relationship with immunological parameters in patients with thoracic tumors undergoing radiotherapy. CRF is a common symptom in cancer patients, particularly those receiving radiotherapy, and it can significantly affect their quality of life and treatment adherence. Despite its prevalence, the pathogenesis and contributing factors of CRF remain unclear.<br /><br />The research involved 128 patients at Beidahuang Group General Hospital, diagnosed with chest tumors and treated with radiotherapy from May 2020 to October 2022. Patients' CRF levels were measured using the Brief Fatigue Inventory before and after radiotherapy. Additionally, immunological parameters, including percentages of CD3T, CD4T, CD8T, NK, and B cells, were evaluated.<br /><br />The findings highlighted that concurrent radiotherapy and chemotherapy, along with higher radiation doses (V10Gy), were significant factors related to exacerbation of CRF after radiotherapy, with an odds ratio indicating a strong predictive capability (AUC=0.72). There was a noticeable decrease in the total number of lymphocytes following radiotherapy, suggesting a connection between CRF and immune system changes.<br /><br />Lymphocyte and platelet levels also shifted post-radiotherapy for those with and without CRF exacerbation, with notable changes in CD3T, CD8T, CD4/CD8 T cells ratio, NK cells, and B cells. The results underline the presence of immune-related mechanisms contributing to CRF.<br /><br />Conclusively, the study suggests that tumor patients typically experience aggravated CRF during radiotherapy. Factors such as concurrent chemotherapy and specific radiation dosage parameters appear to independently influence CRF's severity, emphasizing the need for tailored interventions to address immune changes and improve patient outcomes.

Keywords

cancer-related fatigue

thoracic tumors

radiotherapy

immunological parameters

quality of life

treatment adherence

lymphocytes

chemotherapy

immune system

tailored interventions